Literature DB >> 18162238

Graft failure after allogeneic hematopoietic cell transplantation.

Jonas Mattsson1, Olle Ringdén, Rainer Storb.   

Abstract

Graft failure is a significant complication following allogeneic hematopoietic cell transplantation (alloHCT). It may result from rejection caused by recipient T cells, natural killer (NK) cells, or antibodies. It is increased in HLA-mismatched grafts, unrelated grafts, T cell-replete transplants, sensitized patients, and in patients treated with reduced-intensity conditioning (RIC). In recipients of unrelated grafts, graft failure is increased in patients receiving major AB0 blood group mismatched transplants (P = .008). Recent data also suggest that donor-specific antibodies to CD34(+)/VEGFR-2(+) cells may be involved in graft failure after alloHCT. Graft failure may be overcome by more intensified conditioning, increased cell dose, or more effective immunosuppression. With more frequent use of RIC, cord blood grafts and other HLA-mismatched transplants, graft failure is an increasing problem after alloHCT.

Entities:  

Mesh:

Year:  2008        PMID: 18162238      PMCID: PMC2344125          DOI: 10.1016/j.bbmt.2007.10.025

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  62 in total

1.  Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.

Authors:  H Zetterquist; J Mattsson; M Uzunel; I Näsman-Björk; P Svenberg; L Tammik; G Bayat; J Winiarski; O Ringdén
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

2.  Rejection of marrow from DLA-identical canine littermates given transfusions before grafting: antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells.

Authors:  R Storb; P L Weiden; H J Deeg; T C Graham; K Atkinson; S J Slichter; E D Thomas
Journal:  Blood       Date:  1979-08       Impact factor: 22.113

3.  Effect of prior blood transfusions on marrow grafts: abrogation of sensitization by procarbazine and antithymocyte serum.

Authors:  R Storb; G L Floersheim; P L Weiden; T C Graham; H J Kolb; K G Lerner; M L Schroeder; E D Thomas
Journal:  J Immunol       Date:  1974-04       Impact factor: 5.422

Review 4.  Mixed chimerism: preclinical studies and clinical applications.

Authors:  P A McSweeney; R Storb
Journal:  Biol Blood Marrow Transplant       Date:  1999       Impact factor: 5.742

5.  Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection.

Authors:  J Dubovsky; H Daxberger; G Fritsch; D Printz; C Peters; S Matthes; H Gadner; T Lion; N Muller-Bérat
Journal:  Leukemia       Date:  1999-12       Impact factor: 11.528

6.  A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation.

Authors:  Katarina Le Blanc; Mats Remberger; Mehmet Uzunel; Jonas Mattsson; Lisbeth Barkholt; Olle Ringdén
Journal:  Transplantation       Date:  2004-10-15       Impact factor: 4.939

7.  Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients.

Authors:  D Glotz; J P Haymann; N Sansonetti; A Francois; V Menoyo-Calonge; J Bariety; P Druet
Journal:  Transplantation       Date:  1993-08       Impact factor: 4.939

8.  Engraftment of DLA-nonidentical bone marrow facilitated by recipient treatment with anti-class II monoclonal antibody and methotrexate.

Authors:  H J Deeg; G E Sale; R Storb; T C Graham; F Schuening; F R Appelbaum; E D Thomas
Journal:  Transplantation       Date:  1987-09       Impact factor: 4.939

9.  VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism.

Authors:  Hans-Peter Gerber; Ajay K Malik; Gregg P Solar; Daniel Sherman; Xiao Huan Liang; Gloria Meng; Kyu Hong; James C Marsters; Napoleone Ferrara
Journal:  Nature       Date:  2002-06-27       Impact factor: 49.962

10.  Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis).

Authors:  A Stucki; W Leisenring; B M Sandmaier; J Sanders; C Anasetti; R Storb
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

View more
  49 in total

1.  Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study.

Authors:  Suman Paul; Marianna Zahurak; Leo Luznik; Richard F Ambinder; Ephraim J Fuchs; Javier Bolaños-Meade; Nina Wagner-Johnston; Lode J Swinnen; Laura Schoch; Ravi Varadhan; Richard J Jones; Douglas E Gladstone
Journal:  Biol Blood Marrow Transplant       Date:  2020-06-24       Impact factor: 5.742

2.  Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation.

Authors:  K Ishiyama; J Takeda; T Kondo; N Sugimoto; H Kawabata; T Kitano; A Takaori-Kondo
Journal:  Bone Marrow Transplant       Date:  2016-02-15       Impact factor: 5.483

Review 3.  Evaluation of TCR repertoire diversity in patients after hematopoietic stem cell transplantation.

Authors:  Yangqiu Li; Ling Xu
Journal:  Stem Cell Investig       Date:  2015-09-28

4.  Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.

Authors:  Stephanie B Tsai; Hongtao Liu; Tsiporah Shore; Yun Fan; Michael Bishop; Melissa M Cushing; Usama Gergis; Lucy Godley; Justin Kline; Richard A Larson; Guadalupe Martinez; Sebastian Mayer; Olatoyosi Odenike; Wendy Stock; Amittha Wickrema; Koen van Besien; Andrew S Artz
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-19       Impact factor: 5.742

Review 5.  Autophagy and haematopoietic stem cell transplantation.

Authors:  Lucie Leveque; Laetitia Le Texier; Katie E Lineburg; Geoffrey R Hill; Kelli P A MacDonald
Journal:  Immunol Cell Biol       Date:  2014-11-04       Impact factor: 5.126

6.  Programmable microencapsulation for enhanced mesenchymal stem cell persistence and immunomodulation.

Authors:  Angelo S Mao; Berna Özkale; Nisarg J Shah; Kyle H Vining; Tiphaine Descombes; Liyuan Zhang; Christina M Tringides; Sing-Wan Wong; Jae-Won Shin; David T Scadden; David A Weitz; David J Mooney
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-16       Impact factor: 11.205

7.  Early peripheral blood and T-cell chimerism dynamics after umbilical cord blood transplantation supported with haploidentical cells.

Authors:  M Kwon; C Martínez-Laperche; P Balsalobre; D Serrano; J Anguita; J Gayoso; J L Díez-Martín; I Buño
Journal:  Bone Marrow Transplant       Date:  2013-11-11       Impact factor: 5.483

8.  Reduced-intensity conditioning regimen with low-dose ATG-F for unrelated bone marrow transplant is associated with lower non-relapse mortality than a regimen with low-dose TBI: a single-center retrospective analysis of 103 cases.

Authors:  Shigeo Fuji; Niina Ueno; Nobuhiro Hiramoto; Yoshitaka Asakura; Kimikazu Yakushijin; Yutaro Kamiyama; Saiko Kurosawa; Sung-Won Kim; Yuji Heike; Takuya Yamashita; Takahiro Fukuda
Journal:  Int J Hematol       Date:  2013-10-04       Impact factor: 2.490

9.  Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation.

Authors:  Thissiane L Gonçalves; Dalila M Benvegnú; Gabriela Bonfanti
Journal:  Oxid Med Cell Longev       Date:  2009 Apr-Jun       Impact factor: 6.543

10.  A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells.

Authors:  Assaf Lask; Eran Ophir; Noga Or-Geva; Adva Cohen-Fredarow; Ran Afik; Yaki Eidelstein; Shlomit Reich-Zeliger; Bar Nathansohn; Matthias Edinger; Robert S Negrin; David Hagin; Yair Reisner
Journal:  Blood       Date:  2013-02-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.